The local community doctor has an important role in recognizing, diagnosing, and managing myelofibrosis, said Naveen Pemmaraju, MD, associate professor in the Department of Leukemia at MD Anderson Cancer Center.
The local community doctor has an important role in recognizing, diagnosing, and managing myelofibrosis, said Naveen Pemmaraju, MD, associate professor in the Department of Leukemia at MD Anderson Cancer Center.
Transcript
Do primary care physicians frequently play a role in the diagnosis of myelofibrosis or specialist referral?
Myelofibrosis is often thought of as fairly rare blood cancer, possibly something on the order of 4 to 6 patients out of every 100,000 diagnosed in the United States. However, as with any rare or less common blood cancer, there might be more patients walking around that just haven’t been diagnosed. So, with myelofibrosis and [myeloproliferative neoplasms] in general, the community practice provider plays a very important role in both the recognition, diagnosis, and management.
Of course, I work at an academic center, and I always encourage any patient and any doctor to seek a second or even a third opinion and to be referred to a major academic center. But let’s remember that in rare diseases it’s only rare to others. But when you have that disease, it’s your disease and your body. And so, yes, I do encourage that the local community doctor has a very important role to recognize this disease, diagnose, and we can comanage together. So, that’s the model that I favor: having multiple doctors involved; academic physicians, community physicians working hand in hand for maximal patient care for patients with myelofibrosis.
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
2 Commerce Drive
Cranbury, NJ 08512